Novartis and Bristol Myers Squibb halted multiple autoimmune CAR-T trials after safety concerns tied to immune-related adverse events, according to reports. In Novartis’ case, three patients died in CD19-directed CAR-T trials following a dangerous immune system response, prompting the company to pause enrollment and continue safety review. Bristol Myers also paused its zola-cel program and other development activity, with safety events under review. These pauses emphasize the ongoing challenge of translating CAR-T safety across indications, particularly where tumor biology and immune activation pathways may differ from hematologic settings. Market and clinical attention will likely focus on updated monitoring plans, stopping rules, and whether trial protocols can identify higher-risk profiles before resuming enrollment.